Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ, MEHMET; COŞKUN, HASAN; Korkmaz, Levent; Kocer, Murat; Turhal, Nazim; ENGİN, HÜSEYİN; Dede, Isa; PAYDAŞ, SEMRA; Oksuzoglu, Berna; Bozcuk, Hakan; DEMİRKAZIK, AHMET

doi:10.1016/j.clgc.2016.04.021

Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.14, sa.4, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 4
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.clgc.2016.04.021
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Cytokine therapy, VEGF inhibitors, Progression free survival, Sorafenib, Sunitinib, ENDOTHELIAL GROWTH-FACTOR, SUNITINIB, INTERLEUKIN-2, THERAPY, SU11248
Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.